Merck to Buy Acceleron for About $11.5 Billion in Rare Disease Drug PushUS News | The Epoch Times

Merck & Co. is buying Acceleron Pharma Inc. for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring in fresh revenue. The deal gives Merck access to Acceleron’s rare disease drug candidate, sotatercept, which the company expects to be a multi-billion dollar peak sales opportunity, and comes as Keytruda moves toward the loss of market exclusivity in 2028. The lung cancer treatment accounted for 36.7 percent, or $4.18 billion, of Merck’s total sales in the second quarter. Sotatercept is currently in a late-stage study, testing it as a treatment for a rare cardiovascular disease called pulmonary arterial hypertension (PAH), a type of high blood pressure that affects blood vessels in the lungs. Merck sees PAH as a roughly $7.5 billion market by 2026. The drugmaker will pay $180 per Acceleron share in cash, representing a premium of about 2.6 percent to the …

Leave a Reply

Your email address will not be published.

Next Post

Tow Truck Driver Pleads Guilty to Using Vehicle to Steal CarsUS News | The Epoch Times

Thu Sep 30 , 2021
FULLERTON, Calif.—A tow truck driver with a criminal record has been sentenced to 270 days in jail for using his vehicle to steal several cars in Fullerton, according to court records obtained Sept. 29. Kevin Patrick Cannata, 36, of Anaheim, used his tow truck to steal vehicles between mid-February and […]

Chief Editor

Johny Watshon

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur

Quick Links

Newsletter Signup

Sign up now and never miss a thing!

You're Signed Up!

Now that you are signed up, we will send you exclusive offers periodically.